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Progression and regression of left
ventricular hypertrophy and myocardial
fibrosis in a mouse model of hypertension
and concomitant cardiomyopathy
Jacek Kwiecinski1, Ross J. Lennen1, Gillian A. Gray1, Gary Borthwick1, Lyndsey Boswell2, Andrew H. Baker1,
David E. Newby1, Marc R. Dweck1 and Maurits A. Jansen1*
Abstract
Background: Myocardial fibrosis is observed in multiple cardiac conditions including hypertension and aortic stenosis.
Excessive fibrosis is associated with adverse clinical outcomes, but longitudinal human data regarding changes in left
ventricular remodelling and fibrosis over time are sparse because of the slow progression, thereby making longitudinal
studies challenging. The purpose of this study was to establish and characterize a mouse model to study the
development and regression of left ventricular hypertrophy and myocardial fibrosis in response to increased blood
pressure and to understand how these processes reverse remodel following normalisation of blood pressure.
Methods: We performed a longitudinal study with serial cardiovascular magnetic resonance (CMR) imaging every 2weeks
in mice (n= 31) subjected to angiotensin II-induced hypertension for 6 weeks and investigated reverse remodelling
following normalisation of afterload beyond 6weeks (n= 9). Left ventricular (LV) volumes, mass, and function as well as
myocardial fibrosis were measured using cine CMR and the extracellular volume fraction (ECV) s.
Results: Increased blood pressure (65 ± 12 vs 85 ± 9mmHg; p< 0.001) resulted in higher indices of LV hypertrophy (0.09
[0.08, 0.10] vs 0.12 [0.11, 0.14] g; p< 0.001) and myocardial fibrosis (ECV: 0.24 ± 0.03 vs 0.30 ± 0.02; p< 0.001) whilst LV ejection
fraction fell (LVEF, 59.3 [57.6, 59.9] vs 46.9 [38.5, 49.6] %; p< 0.001). We found a strong correlation between ECV and
histological myocardial fibrosis (r = 0.89, p < 0.001).
Following cessation of angiotensin II and normalisation of blood pressure (69 ± 5 vs baseline 65 ± 12mmHg; p= 0.42), LV
mass (0.11 [0.10, 0.12] vs 0.09 [0.08, 0.11] g), ECV (0.30 ± 0.02 vs 0.27 ± 0.02) and LVEF (51.1 [42.9, 52.8] vs 59.3 [57.6, 59.9] %)
improved but remained impaired compared to baseline (p< 0.05 for all). There was a strong inverse correlation between
LVEF and %ECV during both systemic hypertension (r =− 0.88, p< 0.001) and the increases in ECV observed in the first two
weeks of increased blood pressure predicted the reduction in LVEF after 6weeks (r = − 0.77, p< 0.001).
Conclusions:We have established and characterized angiotensin II infusion and repeated CMR imaging as a model of LV
hypertrophy and reverse remodelling in response to systemic hypertension. Changes in myocardial fibrosis and alterations in
cardiac function are only partially reversible following relief of hypertension.
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Introduction
Pressure overload heart disease with concomitant myocar-
dial fibrosis is observed in multiple common cardiac con-
ditions including hypertension and aortic stenosis [1–8].
While there is growing evidence that excessive fibrosis is
associated with adverse clinical outcomes, longitudinal hu-
man data regarding changes in left ventricular (LV) remod-
elling and fibrosis over time are sparse. The lack of such
data is largely due to the natural history of pressure over-
load heart disease, with conditions such as hypertension
and aortic stenosis progressing slowly over many years
and decades thereby making longitudinal studies challen-
ging. In addition, little is known about adverse remodel-
ling reversibility once the trigger is removed [9]. Such
insights are of particular interest in aortic stenosis where
there is growing interest in optimizing the timing of aortic
valve replacement ideally using novel objective biomarkers
of LV decompensation [10–13].
Rodent models of pressure overload cardiomyopathy
have been developed and potentially allow monitoring of
disease progression, from the onset of pressure overload
out to the advanced stages of heart failure [14–16]. These
models can therefore provide longitudinal data that are
lacking in humans and can potentially do so using ad-
vanced imaging techniques that can be directly translated
in to humans [17, 18]. One of the most widely used
models of pressure overload heart disease is transverse
aortic constriction. Unfortunately, this approach involves
a high dropout rate of animals related to surgery and with
the band placed distal to the innominate artery causes cor-
onary congestion and a disease state more similar to aortic
coarctation than aortic stenosis or hypertension [9]. Fur-
thermore, removal of the band is challenging, and results
in incomplete relief of the obstruction making the study of
reverse remodelling difficult [19]. Consequently, only a
few studies have investigated reverse remodelling upon re-
moval of the pressure overload and these did not include
advanced imaging techniques [20–22].
The purpose of this study was to develop and characterize a
mouse model of reversible hypertension induced cardiomyop-
athy and to use state-of-the-art in vivo imaging to interrogate
LV hypertrophy, myocardial fibrosis, and cardiac function
both before and after afterload reversal. Ultimately, our aim
was to create a model that might help develop novel non-
invasive biomarkers of LV decompensation in response to
pressure overload and provide insight in to the time-course of
clinically relevant conditions.
Methods
Study protocol
Thirty-one 14 ± 2 weeks, male C57BL/6 J mice (Envigo,
Indianapolis, Indiana, USA) were subjected to a continu-
ous angiotensin II infusion at 480 ± 34 ng/kg/min for up
to 6 weeks (Fig. 1). A subset (n = 9) of the animals
receiving a 6-week infusion were assessed for an add-
itional 28 days after discontinuation of the infusion to
allow investigation of reverse remodelling. Baseline mea-
surements were taken at the start of the study, and before
any intervention so that each animal could serve as its own
control and intra-subject analysis could be performed. A
control cohort of animals (14 ± 2week male C57BL/6 J mice)
received a placebo infusion of saline (0.9% NaCl) (n= 9)
and was included to study and correct for any age- and
procedure-related effects not attributable to angiotensin II.
Throughout the experiments, animals were on a regular
chow diet, housed 5 mice per cage in a 12 h:12 h light/dark
cycle in animal facilities at the University of Edinburgh.
Animal model of systemic hypertension
To subject animals to systemic hypertension, subcutaneously
implanted osmotic minipumps (Alzet, Cupertino, California,
USA) were used [23]. Minipumps were prepared to deliver
angiotensin II (Ang-II, Sigma-Aldrich, Darmstadt, Germany)
at predetermined rates of infusion [22]. Implantation was per-
formed surgically under inhalational anaesthesia (isoflurane
(1.5–2%), supplemental data). To monitor pressure overload,
animals underwent serial blood pressure measurements using
a Letica LE 5002 Non-Invasive Blood Pressure System
(Panlab, Cornellá, Spain) which operates on the same basis as
clinically used sphygmomanometers (tail cuff method). Prior
to study commencement, mice were trained for tail cuff pleth-
ysmography in order to decrease animal stress related to
measurement acquisition and to improve reproducibility. Dur-
ing the experimental period, mice were subjected to plethys-
mography after each imaging session. After 2 preliminary
measurements, at least three recordings of systolic, diastolic
and mean arterial pressure were recorded in each animal.
Cardiovascular magnetic resonance imaging
All animals underwent serial cardiovascular magnetic res-
onance (CMR) imaging to assess LV structure and func-
tion as well as myocardial fibrosis. CMR was performed
initially at baseline, before the onset of hypertension (so
that progression of adverse remodelling could be com-
pared to baseline), and then every 2 weeks during angio-
tensin II infusion. In the reverse remodelling subgroup, a
final CMR scan was performed 4 weeks after the angioten-
sin II infusion had been discontinued. At the end of the
final imaging session, animals were sacrificed by exsan-
guination under deep anaesthesia with the heart stored for
further histological analysis.
All CMR scans were performed on a 7 T preclinical
horizontal-bore CMR system (Agilent Technologies, Santa
Clara, CA, USA) equipped with a 33-mm inner diameter
quadrature radiofrequency coil for mice (Rapid Biomedical,
Rimpar, Germany). Animals were anaesthetised using iso-
flurane (3% isoflurane in 1.0 L/min oxygen for induction and
1.5–2% isoflurane in 0.5 L/min O2/0.5 L/min air for
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maintenance). Prior to imaging, an Anicath 26G cannula
(Millpledge Veterinary, Clarborough, UK) was placed intra-
peritoneally for administration of the gadolinium-based
contrast agent (gadobenate dimeglumine 1 μL/g body
weight [Multihance]; Bracco Diagnostics, Princeton,
New Jersey, USA). Animals were placed in a CMR cradle
with electrocardiogram (ECG) leads placed subcutaneously.
The animals were positioned supine with hearts in the
centre of the coil, and in the centre of the CMR scanner. A
pressure transducer was placed under the torso for con-
stant monitoring of respiration (CMR-compatible Small
Animal Monitoring and Gating System, SA Instruments,
Stony Brook, New York, USA), and a rectal probe was
inserted to monitor and maintain body temperature at
37 ± 0.5 °C via a feedback-controlled warm air system
(CMR-compatible Small Animal Heating System, SA In-
struments). Throughout the imaging session we adjusted
the warm air system to maintain target body temperature
and as a result a stable heart rate at 530–600 beats/min and
a respiratory rate of 45–75 breaths/min.
Scout images were taken to confirm correct position-
ing and to orientate 1.0-mm short axis slices covering
the heart. T1 mapping for calculation of regional myo-
cardial T1 relaxation times was accomplished using a
gradient-echo, cardiac-gated modified Look-Locker in-
version recovery sequence (MoLLI) during which 30 im-
ages of a single mid-ventricular slice were acquired at
unique inversion times (dependent on heart rate, ranging
from approximately 0.10 to 3.00 s) with the recovery
time after each slice-selective inversion pulse of about
4.5 s, as described previously [24, 25]. Imaging readout
was with a cardiac fast gradient echo (repetition time
2.8 ms; echo time 1.4 ms; flip angle 10°, matrix 128 ×
128; field of view 30 × 30 mm2; in-plane resolution =
0.23 × 0.23 mm2; trigger delay 0.5 × R-R; slice thickness
1.5 mm;). We acquired eight phase-encoding echos per
segment and 8 signal averages were used to compensate
for respiratory motion. After acquisition of a baseline T1
map, gadobenate dimeglimine was injected via the intra-
peritoneal cannula, and a second T1-mapping dataset
was acquired 20 min post-injection. During the time be-
tween the T1-mapping acquisitions, cine images were
acquired for structural and functional assessment. The
short axis, vertical and horizontal long axis cardiac
images were acquired using an ECG triggered and
respiratory-gated gradient echo sequence (TR/TE = 5.2/
1.3 ms, flip angle: 15°) with gradient and radiofrequency
spoiling. Eighteen phases were acquired with a field of
view of 30 × 30mm, a 128 × 128 matrix, and 2 signal
averages were used. For the LV short axis, nine
consecutive 1-mm-thick slices were acquired, which
encompassed the entire heart from base to apex. Late
gadolinium enhancement (LGE) imaging was performed
between 12 and 18min after contrast administration
with a short-axis cardiac-triggered/respiratory-gated T1-
weighted gradient echo inversion-recovery scan with the
following imaging parameters: TR: 1000ms (depending
on respiration rate), TE: 1.45 ms, field of view: 30 × 30
mm, number of signal averages: 4, inversion time: 560
ms, flip angle: 90°, nine 1-mm thick slices covering the
entire left ventricle.
Image analysis
Data were analysed using cvi42 software (Circle CVI,
Calgary, Alberta, Canada). The short axis cine LV images
were used for the assessment of LV volumes, mass and
ejection fraction. The epicardial and endocardial con-
tours were carefully identified and planimetered in end-
systole and end-diastole for LV volume quantification.
The LV mass was calculated from the total myocardial
volume (excluding trabeculations and papillary muscles)
multiplied by the density of the myocardium (1.05 g/
mL). Maximal LV wall thickness was evaluated in all 17
LV segments from cine images of the LV in end-diastole
[26]. For LV diffuse fibrosis, we calculated the extracel-
lular volume fraction (ECV) derived from pre- and post-
Fig. 1 Schematic diagram of study the study protocol. MRI was performed at baseline, during Angiotensin-II infusion (2, 4 and 6 weeks) and after
a 4-week recovery period. Animals were sacrificed at these time points and hearts analysed using histology (HISTO) methods. Control animals are
depicted in green and Angiotensin-II treated animals in brown. * Due to a tissue fixation error 2 hearts from animals sacrificed at 6 weeks and 1
heart from the 10 week cohort was not suitable for staining and histological analysis
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contrast myocardial T1 values corrected for blood-pool
T1. The ECV% was calculated according to: ECV = parti-
tion coefficient × [1-hematocrit]; where partition coeffi-
cient = [ΔR1myocardium/ΔR1blood-pool] and ΔR1 = (1/
post-contrast T1–1/pre-contrast T1). To avoid blood-
pool contamination and partial volume effects, we used
a mid-myocardial region of interest for the T1-mapping
analysis. A two-pixel wide myocardium and ventricular
boundary zone was excluded from all applicable slices.
We actively searched for areas of LGE within the
myocardium.
Histology
Histological validation was performed for each CMR tech-
nique used to measure myocardial fibrosis. After the final
imaging session, animals were euthanized by exsanguin-
ation under isoflurane anaesthesia. The heart was re-
moved and transferred into 10% neutral buffered formalin
(Cellstor, CellPath, Newton, UK) for fixation for at least
20 h. After fixation, hearts were processed and embedded
in paraffin in a short axis orientation so that the cut sec-
tions would all show the ventricle lumen. Slides were
stained in a 0.1% sirius red solution in saturated picric acid
(Picrosirius red, Sigma, Dorset, UK). All picrosirius red
stained slides images were acquired on the AxioScan Z1
(Carl Zeiss, Oberkochen, Germany) and analysed using
Image-Pro Premiere 9.1 (MediaCybernetics, Rockville,
Maryland, USA) using a tissue specific threshold. One
midventricular slice was analysed for each heart to enable
correlation with T1 mapping data. The area of fibrosis
was expressed as a percentage of the total myocardial area
in that section (see also Supplemental Data).
Statistical analysis
Continuous variables were tested for distribution with
the Shapiro-Wilk test. Data are presented as mean ± SD,
median [interquartile range] or percentages where ap-
propriate. Differences between groups were assessed
with the use of a 2-sided Student t-test, paired Student
t-test, ANOVA for continuous variables, Wilcoxon rank-
sum test for ordinal variables and the χ2 test or Fisher’s
exact test for categorical data. The relationship between
2 continuous variables was assessed using the Pearson’s
correlation coefficient. A 2-sided p < 0.05 was considered
statistically significant.
Results
LV remodelling under systemic hypertension
Mean arterial pressure (MAP) was elevated after 2 weeks
of angiotensin II infusion compared to baseline (84 ± 14
vs 65 ± 12mmHg, p < 0.001) and remained stable for the
remainder of the infusion phase (p > 0.50; Table 1). Both
LV maximum wall thickness and LV mass increased
during angiotensin II infusion (0.73 [0.71,0.76] vs 0.84
[0.81, 0.86] mm, p = 0.001 and 0.09 [0.08, 0.10] vs 0.10
[0.10, 0.12] g, p < 0.001 respectively). Wall thickness and
LV mass were elevated after 2 weeks and increased fur-
ther up to the 4-week time point (0.84 [0.81, 0.86] vs
0.88 [0.80, 0.95] mm, p < 0.001 and 0.11 [0.10, 0.12] vs
0.12 [0.11, 0.14] g, p < 0.001) after which both plateaued
(Table 1). Such LV remodelling was not observed in
control animals (Table 1).
Histological assessment of myocardial fibrosis
Hearts from 28 animals were available for histological
analysis and validation of the CMR fibrosis measure-
ments (Fig. 1, Fig. 2A). While control animals showed
no difference in fibrosis over time we observed an in-
crease in myocardial fibrosis in animals exposed to the
angiotensin II infusions compared to control animals
(4.4, [3.5, 5.8] vs 10.1 [8.7, 12.9] % and baseline (4.5, [3.5,
5.8] vs 10.1 [8.7, 12.9], both p < 0.001). There was a
strong correlation between the histological assessment
of myocardial fibrosis (% myocardium comprised of fi-
brosis) and the ECV% as measured by CMR (r = 0.89,
p = 0.001; Fig. 2). Similar correlations were observed be-
tween histological fibrosis and native T1 (r = 0.80, p < 0.001)
and post contrast T1 (r = − 0.75, p < 0.001).
LV fibrosis and function under systemic hypertension
While the changes in native T1 relaxation times during ex-
posure to systemic hypertension did not reach statistical
significance (p = 0.10), ECV demonstrated progressive in-
creases. This increase in ECV demonstrated a similar pat-
tern of change as the blood pressure with an initial increase
(0.24 ± 0.03 vs 0.30 ± 0.04, p = 0.004) followed by a plateau
phase after 4 weeks (p > 0.40). Consistent with this, LVEF
also demonstrated an ongoing gradual reduction with time
spent on the angiotensin II infusion (LVEF 59.3 [57.6, 59.9]
% at baseline, 52.4 [47.7, 53.9] % at 2 weeks, 49.5 [41.2,
51.7] % at 4 weeks and 46.9 [38.5, 49.6] % at 6 weeks;
p < 0.001 for trend) (Figs. 3 and 4). Within our study popula-
tion we did not observe any myocardial late gadolinium
enhancement indicative of focal replacement fibrosis.
Reverse remodelling
Four weeks after the end of the angiotensin II infusion,
reversal of the pressure overload state was observed with
mean arterial blood pressure values returning to baseline
(p = 0.42 for difference, Fig. 4A). In response to the nor-
malisation of blood pressure, LV mass and ECV all
regressed (p < 0.01; Table 1). However, this reverse re-
modelling was only partial with none of these measures
returning to their baseline values (Fig. 4). Indeed, ECV
only partially resolved, with values reducing from 0.30 ±
0.02 during the infusion to 0.27 ± 0.02 (p = 0.001) 4
weeks following its discontinuation compared to baseline
values of 0.24 ± 0.03 (p = 0.06). Importantly, the LVEF
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again demonstrated a similar pattern to ECV, showing a
trend towards recovery (46.9 [38.5, 49.6] vs 51.1 [42.9,
52.8] %, p = 0.10) yet remaining lower at 4 weeks than at
baseline (59.3 [57.6, 59.9] vs 51.1 [42.9, 52.8] %, p =
0.029; Table 1). The LV EDV remained elevated: 0.08
[0.07, 0.10] mL compared to 0.08 [0.07, 0.10] mL during
pressure overload (p = 0.70).
ECV% is associated with systolic function
There was a moderate inverse correlation between LVEF
and ECV% values during pressure loading (r = − 0.54,
p < 0.001 at 6 weeks, Table 2). On multivariable linear
regression analysis, ECV% was independently associated
with LVEF independent of MAP and LV mass (Table 2).
We found a strong correlation between the in-
creases in ECV observed in the first two weeks of
systemic hypertension (from baseline to week 2) and
the reduced LVEF after 6 weeks (r = − 0.77, p < 0.001;
Fig. 5).
Discussion
In this study, we have used the angiotensin II infusion
model of hypertension to establish an animal model of
reverse remodelling following load normalization. This
model has allowed us to assess how the hypertrophic re-
sponse and myocardial fibrosis develop in response to
an increased afterload and then reverse remodels once
that stimulus is removed. We believe our model will
allow improved understanding of the processes under-
lying LV decompensation in patients with aortic stenosis
and hypertension. In this study, we have demonstrated
that myocardial fibrosis appears to be the primary deter-
minant of LV dysfunction both before and after reversal
of systemic hypertension. Further studies should investi-
gate whether reversing systemic hypertension earlier
might potentially lead to complete recovery in LV func-
tion and whether the optimal timing can be identified
using imaging.
Our preclinical model offers several important advan-
tages. Using state-of-the-art in vivo CMR imaging, we
Table 1 Left ventricular remodelling under pressure overload and after load normalization
Baseline 2 weeks 4 weeks 6 weeks 4 weeks
post-infusion
Statistics
I
P value
for a
trend
(ANOVA)
Statistics
II
P value
6 week
vs 4
weeks
post
infusion
Animals Experimental
n = 31
Control
n = 9
Experimental
n = 31
Control
n = 9
Experimental
n = 26
Control
n = 7
Experimental
n = 23
Control
n = 7
Experimental
n = 9
MAP, mm
Hg
65.1 ± 12.0 65.3 ±
10.8
84.2 ± 13.6 64.8 ±
11.6
86.5 ± 7.1 66.9 ±
12.1
84.7 ± 9.2 64.0 ±
13.2
68.8 ± 5.4 < 0.001 < 0.001
EDV, ml 0.058 [0.053,
0.063]
0.059
[0.054,
0.063]
0.071 [0.066,
0.081]
0.060
[0.056,
0.064]
0.074 [0.065,
0.086]
0.062
[0.060,
0.065]
0.083 [0.073,
0.097]
0.065
[0.060,
0.067]
0.081 [0.067,
0.095]
< 0.001 0.60
ESV, ml 0.022 [0.020,
0.025]
0.022
[0.020,
0.025]
0.033 [0.30,
0.040]
0.023
[0.020,
0.024]
0.041 [0.034,
0.045]
0.023
[0.020,
0.026]
0.048 [0.037,
0.055]
0.025
[0.021,
0.027]
0.041 [0.032,
0.063]
< 0.001 < 0.20
Wall
Thickness,
mm
0.73 [0.71,
0.76]
0.72
[0.71,
0.77]
0.84 [0.81,
0.86]
0.74
[0.70,
0.79]
0.88 [0.80,
0.95]
0.73
[0.70,
0.77]
0.86 [0.82,
0.91]
0.75
[0.72,
0.80]
0.82 [0.80,
0.92]
0.001 0.18
LV mass, g 0.091 [0.083,
0.105]
0.090
[0.084,
0.100]
0.108 [0.101,
0.121]
0.089
[0.085,
0.099]
0.121 [0.111,
0.136]
0.095
[0.088,
0.100]
0.123 [0.111,
0.138]
0.099
[0.090
0.103]
0.108 [0.098,
0.116]
< 0.001 0.003
LV ECV, % 0.24 ± 0.03 0.24 ±
0.03
0.30 ± 0.04 0.24 ±
0.04
0.309 ± 0.03 0.24 ±
0.04
0.30 ± 0.02 0.25 ±
0.04
0.27 ± 0.02 0.001 0.001
Heart Rate 561 ± 30 555 ±
28
557 ± 29 553 ±
32
542 ± 37 552 ±
39
543 ± 40 553 ±
41
556 ± 38 0.74 0.58
SV, ml 0.031 [0.027,
0.035]
0.031
[0.027,
0.036]
0.033 [0.029,
0.035]
0.032
[0.029,
0.033]
0.034 [0.028,
0.036]
0.032
[0.028,
0.035]
0.033 [0.031,
0.034]
0.033
[0.031,
0.034]
0.035 [0.031,
0.036]
0.19 0.70
LVEF, % 59.3 [57.6,
59.9]
59.0
[56.5,
60.8]
52.4 [47.7,
53.9]
58.7
[57.1,
60.9]
49.5 [41.2,
51.7]
59.5
[56.2,
61.7]
46.9 [38.5,
49.6]
60.2
[56.9,
61.5]
51.1 [42.9,
52.8]
< 0.001 0.10
ECV – extracellular volume , EDV – end diastolic volume, ESV – end diastolic volume, LVEF- left ventricular ejection fraction, SV – stroke volume. Statistics I:
Repeated Measures ANOVA (baseline, 2 weeks, 4 weeks, 6 weeks). Statistics II: Paired student T test (6 weeks versus 1month post infusion)
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have been able to obtain longitudinal data on myocardial
remodelling within a timespan of months rather than
years or decades as observed in humans. Furthermore, it
facilitates histological correlation with imaging findings,
enabling validation of our CMR markers of fibrosis, in-
cluding ECV, as biomarkers of LV fibrosis. Finally, our
preclinical model provides insights into both the hyper-
trophic response and reverse remodelling using state-of-
the-art longitudinal imaging assessments. While several
studies have utilized transverse aortic constriction as a
model of aortic stenosis, this model has several limita-
tions [14–16]. The surgical technique is associated with
a 25% drop-out of animals in the peri-procedural period
[9]. With the aortic band placed between the origin of
the innominate and left common carotid arteries the
model recreates proximal aortic coarctation leading to
significant hemodynamic consequences. These include
elevated pressure in the innominate, right common
Fig. 2 Fibrosis on histology and T1-mapping data. Examples of diffuse fibrosis in mice subjected to systemic hypertension for 6 weeks on
histology - picrosirius red staining (A). The relationship between fibrosis on histology and the native T1-values (B), post contrast T1-values (C) and
the extracellular volume (D). While native T1 and ECV showed a positive correlation with histological fibrosis due to kinetics of the contrast
agent’s myocardial clearance, post-contrast T1 values are negatively correlated with histological fibrosis. Hearts from 20 hypertensive animals
sacrificed immediately after imaging (during the infusion of angiotensin II at the 2-week (n = 5), 4-week (n = 3) and 6-week (n = 12) timepoint)
were used for this analysis. Pearson’s correlation coefficient
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carotid, coronary and right subclavian arteries as op-
posed to the left subclavian and carotids. In severe con-
striction, perfusion of organs distal to the band can be
maintained through the Willis circle yet this again is not
typical for aortic valve stenosis or hypertension.
Continuous infusion of angiotensin II leads to sys-
temic hypertension and holds major promise in im-
proving our understanding of LV decompensation in
pressure overload conditions and in the development
of novel biomarkers and treatment strategies [27]. In-
deed, in this study, we have demonstrated that reduc-
tions in ejection fraction associated with hypertension
are more closely associated with the total burden of
myocardial fibrosis than the degree of pressure after-
load. Moreover, we observed that reverse remodelling
1 month after load normalization is incomplete with
residual fibrosis again closely associated with residual
systolic impairment. Our findings are in line with the
hypothesis that fibrosis is the principal driver of LV
decompensation in pressure overload [7], a key deter-
minant of LV systolic function and an important
potential therapeutic target. This is a particularly
appealing target given that several drug therapies have
already demonstrated their ability to reduce myocar-
dial fibrosis in other contexts [1, 28]. Indeed, our
model could potentially be used to assess the efficacy
Fig. 3 Cardiovascular magnetic resonance imaging of mice subjected to systemic hypertension. Modified Look-Locker Inversion Recovery T1-
mapping (A). T1 relaxation times for the myocardium and bloodpool are generated from images shown in the upper row. The calculated T1
relaxation times can be used to generate native (blue) and postcontrast (orange) T1 maps. End-diastolic and end-systolic LV short axis images
demonstrating adverse remodelling due to an increased afterload (B). The actual length of the scale bar is 5 mm
Kwiecinski et al. Journal of Cardiovascular Magnetic Resonance           (2020) 22:57 Page 7 of 11
Fig. 4 Adverse remodelling under systemic hypertension. Mean arterial pressure (A), Left ventricular end diastolic volume (B), Left ventricular mass
(C), Extracellular volume fraction (D), LV ejection fraction (E). Thirty-one experimental animals underwent imaging at baseline and 9 animals were
followed in the recovery phase, the exact number of mice scanned at each timepoint is presented in Fig. 1. Repeated measures ANOVA (baseline,
2 week, 4 weeks, 6 weeks). For post-hoc comparisons, see Table 1
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of existing or novel anti-fibrotic therapies before proceed-
ing to expensive clinical trials.
This model might prove of value in determining the
optimal timing of aortic valve replacement. The data
presented here suggest that if pressure overload (hyper-
tension) continues for too long then irreversible fibrosis
will develop in the LV, leading to long term impairment
of systolic function. Further studies should investigate
whether reversing pressure overload earlier might poten-
tially lead to complete recovery in LV function and
whether the optimal timing can be identified using im-
aging or other biomarkers. This strategy could ultimately
then be applied to patients with aortic stenosis, thereby
optimizing the timing of aortic valve replacement.
Limitations
We acknowledge that our study has limitations. While
our model recreates the myocardial response to in-
creased afterload observed in patients with hypertension
and aortic stenosis, it is not a pure model for either.
Moreover, angiotensin II might have triggered diffuse
fibrosis irrespective of the elevated blood pressure [29].
For T1-mapping, we only acquired data from the mid-
ventricle short axis slice potentially introducing a sam-
pling error. In patients, data are usually obtained from 3
slices so that the basal, mid and apical segments are all
interrogated. Since our model of hypertension affects the
entire LV and due to animals’ welfare, we chose to
shorten the image acquisition by focusing on the mid-
ventricle slice. We performed blood pressure measure-
ments immediately after the imaging sessions at the time
animals were recovering from anaesthesia. We found
such an approach to be less stressful for mice whilst
allowing for recording multiple readings. Finally, we only
assessed reverse remodelling at 4 weeks post cessation of
the angiotensin II infusion, therefore we cannot rule out
that the fibrosis burden and LV mass would normalise
during longer follow-up.
Conclusions
Using state-of-the-art in vivo CMR imaging, we have de-
veloped a mouse model of LV hypertrophy and reverse
albeit incomplete remodelling in response to systemic
hypertension which allows tracking of changes in LV re-
modelling, myocardial fibrosis and systolic function. In
this study, we have demonstrated that myocardial fibro-
sis appears to be the primary determinant of LV dys-
function both before and after reversal of pressure
overload.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12968-020-00655-7.
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Abbreviations
CMR: Cardiovascular magnetic resonance; ECV: Extracellular volume;
EDV: End-diastolic volume; ESV: End-systolic volume; LGE: Late gadolinium
enhancement; LV: Left ventricle/left ventricular; LVEF: Ejection fraction;
MAP: Mean arterial pressure; MOLLI: Modified Look-Locker inversion recovery;
SV: Stroke volume; TD: Delay time; TE: Echo time; TR: Repetition time
Table 2 Univariable and multivariable linear regression analysis to examine association of variables with LV ejection fraction after 6
weeks of pressure overload
Variables Univariable Multivariable – Model 1 (included
early ECV% change)
R-Sq = 0.62
Multivariable – Model 2 (included ECV% at
6 weeks)
R-Sq =0.54
Relative change in LVEF
(95% CI)
P- value Relative change in LVEF
(95% CI)
P- value Relative change in LVEF (95% CI) P- value
MAP, per 5 mmHg −2.8 (−5.4- -0.1) 0.04 −1.3 (3.0–0.4) 0.23 −1.9 (−3.9–0.1) 0.11
LV mass, per 1 mg 0.1 (−0.05–0.3) 0.08 −0.2 (−0.5–0.1) 0.27 0.2 (−0.1–0.5) 0.21
Early change in ECV%, per 1% − 2.1 (− 2.9- -1.3) < 0.001 −2.2 (− 2.9- -1.5) < 0.001
ECV% − 1.6 (− 2.3- -0.8) < 0.001 −1.5 (− 2.2 - -0.7) < 0.001
ECV% – extracellular volume fraction, LVEF – left ventricular ejection fraction, MAP – mean arterial pressure
Fig. 5 Diffuse fibrosis and systolic function in 23 animals which were
subjected to a continuous angiotensin II infusion for 6 weeks. Early
changes in ECV predict later reductions in LVEF. Pearson’s
correlation coefficients
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